pHyph shows excellent medical effect with high cure rate and low risk of recurrence in bacterial vaginosis. At day 7 over 60% of patients report abscence of symtoms and at day 25, 80% are still free from BV.

News

More news

Convincing efficacy and safety results

pHyph shows rapid symptom relief and longterm effect. Already at first day of treatment many patients see a relief in symptoms and at day 7 nearly 70% report absence of symptoms. When treated, the patients stay well and after 35 days, 85% of patients are still free from BV, compared to 54-77% with antibiotics.

90% Symptom reduction

In our most recent and largest clinical trial so far, symptom reduction was seen in 90% of patients.

Day 7

At day 7 nearly 70% of patients report abscence of symtoms

Day 25

80% are still free from BV

Read more about clinical results

Gedea Biotech aims to make a sustainable contribution to global women’s health and to limit the unnecessary use of antibiotics. We develop a treatment that is safe to use, effective and free of antibiotics, to solve the problem with vaginal infections and their complications.

Annette Säfholm, CEO
annette.safholm@gedeabiotech.com
+46 (0) 708 - 91 86 81

According to the World Health Organization (WHO), antibiotic resistance is one of the greatest threats to global health of our time. A total of nearly 3% of all antibiotics prescribed to women in Sweden are used to treat bacterial vaginosis.*

*) Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2019.